Endocrinology · CGM + RPM
Remote Monitoring for Endocrinology
Two patients with the same A1c can have completely different days. One is steady; the other swings between overnight lows and post-meal spikes and averages out to the same number. Time in range tells you which patient you have.
CGM integration + time in rangeInsulin titration supportHIPAA · SOC 2 Type II
Glycaemic pictureLive
Time in range70–180 mg/dL, 14 days
62%Nocturnal lowsBelow 70 overnight
2 this weekFasting glucoseCellular meter
171 mg/dLBlood pressureComorbid across the panel
136/86>70%time in range, the common clinical target
<4%time below 70 mg/dL, the safety target
95249 · 95250the CGM service codes
~$160RPM + CCM per patient per month
Overview
Time in Range Is the Number You Manage
Time in range has largely replaced the single A1c as the metric endocrinology teams manage to, for a straightforward reason: an A1c is an average, and averages hide the two things that actually hurt patients. Overnight lows they sleep through, and post-meal spikes they never feel.
A continuous glucose monitor shows you both. That’s what makes it actionable, because it tells you when control is being lost, which determines whether you change the basal dose, the mealtime dose or the timing rather than simply increasing something.
HealthArc brings CGM data into the same dashboard as blood pressure, weight and the rest of the panel, so the endocrinology view and the chronic-care view are the same view, and the CCM documentation is generated from the same activity.
Time in range is the numberMore than 70% between 70–180 mg/dL is the common target.
CGM shows when control is lostWhich determines whether you change basal, mealtime or timing.
CGM bills separately95249 and 95250, distinct from RPM device supply.
>70%Time in range, the common clinical target
Nocturnal hypoglycaemia is the classic miss. The patient sleeps through it, a fingerstick regimen never catches it, and it changes the evening dose the moment it becomes visible.
What we monitor
What an Endocrinology Program Monitors
Glucose in two forms, plus the comorbidities that determine downstream risk.
| Signal | Device | Common target / threshold | What the team does |
|---|---|---|---|
| Time in range | CGM | >70% between 70–180 mg/dL | The primary number for regimen decisions. |
| Time below range | CGM | <4% below 70 mg/dL; minimal below 54 | Safety first. Drives the evening dose more than anything else. |
| Fingerstick glucose | Cellular meter | <70 or >250 mg/dL | For the non-insulin-treated share of the panel. |
| Blood pressure | Cellular BP monitor | 7-day average above goal | Comorbid across most of the panel and a major driver of complications. |
| Weight | Cellular scale | Sustained trend, either direction | Increasingly relevant with GLP-1 therapy. |
Alert thresholds are configured per patient by the ordering clinician and adjusted over time. The values above are common starting points, not clinical guidance, and nothing here establishes a standard of care. Reimbursement figures are approximate national non-facility Medicare averages and vary by locality, facility status, payer and calendar year: verify current rates at cms.gov or with your MAC before you bill.
Devices
Devices for an Endocrinology Panel
CGM where the curve matters. Cellular meters everywhere else.
Continuous Glucose Monitors
Full curves, time-in-range reporting and nocturnal low alerts.
95249 · 95250Cellular Glucose Meters
For the non-insulin-treated share, with no app or pairing.
RPM 99454Blood Pressure Monitors
Three cuff sizes, cellular.
RPM 99454Cellular Weight Scales
Step-on weights, relevant across GLP-1 regimens.
RPM 99454
Programs & billing
Programs an Endocrinology Panel Supports
Remote Patient Monitoring
Meter supply plus monthly treatment-management time.
99453 · 99454 · 99457Chronic Care Management
Diabetes plus a second chronic condition.
99490 · 99439Principal Care Management
When the endocrine condition alone drives the burden.
99424–99427Medication Therapy Management
Insulin and GLP-1 regimen review.
99605–99607Behavioral Health Integration
Diabetes distress, which materially affects adherence.
99484 · 99492
How it runs
How a Month Runs
1
Step 1 of 5
Segment by therapy
Insulin-treated patients get CGM. The rest get cellular meters. The economics differ and so does the workflow.
2
Step 2 of 5
Bring the data in
CGM data and meter readings arrive in one dashboard alongside BP and weight.
3
Step 3 of 5
Review the curve, not the average
Your team works time in range, nocturnal events and post-meal excursions.
4
Step 4 of 5
Adjust with evidence
Regimen changes are made against a pattern rather than a single number.
5
Step 5 of 5
Close the month
CGM services and RPM time documented under their own codes.
FAQs
Endocrinology Remote Monitoring: Common Questions
What is a good time in range?
The widely used consensus target is more than 70% of readings between 70 and 180 mg/dL, with less than 4% below 70 mg/dL and minimal time below 54 mg/dL. Targets are individualised, and older patients or those with hypoglycaemia unawareness are commonly managed to a looser range.
Time in range is more actionable than an A1c because it tells you when control is being lost, which is what determines which part of the regimen to change.
How are CGM services billed?
95249 covers startup, sensor placement, training and printout for patient-owned equipment. 95250 covers practice-supplied equipment with a minimum of 72 hours of continuous recording. 95251 covers interpretation and report.
These are distinct from the RPM device-supply codes used for cellular glucose meters. Verify current rates and payer policy before billing.
Can endocrinology practices bill RPM and CCM together?
Yes, in the same calendar month for the same patient, provided the minutes are tracked separately and the same time is never counted toward both. Most endocrinology patients carry a second chronic condition, so the combination is common.
The practical requirement is one time log across programmes, which is what makes the separation provable if a payer asks.
Which patients should get a CGM rather than a meter?
Insulin-treated patients benefit most, along with anyone with hypoglycaemia unawareness, frequent lows, or an A1c that does not match how they report feeling, which is the classic signature of a patient swinging in both directions around a reasonable average.
For patients on oral agents with stable control, a cellular meter usually answers the clinical question at a fraction of the cost.
Keep reading
Related guides and programs
Design an endocrinology program
Tell us how much of your panel is insulin-treated. That single number drives the device mix and the economics.
Resources
From the HealthArc blog
Practical guidance on remote monitoring, devices and billing. Updated with every new post.
September 1, 2026
Remote Patient Monitoring and Chronic Care Management: The Complete Platform Comparison and Implementation Guide (2026)
Compare RPM and CCM platforms on the five things that decide real-world performance, then implement an RPM program step by step with 2026 CPT rates.
Read articleAugust 25, 2026
Cellular vs Bluetooth Blood Pressure Monitors for RPM: Which One Keeps Patients Compliant?
Cellular or Bluetooth for RPM blood pressure? What CPT 99445 changed in 2026, why 78% of over-65s owning a smartphone breaks the usual argument, and how to match devices per patient.
Read articleAugust 21, 2026
How RPM, CCM and APCM Actually Move Value-Based Care Quality Measures
A measure-by-measure map of what RPM, CCM and APCM can actually influence, the CBP specification detail most programs miss, and why PDC targeting should start at 79%.
Read articleHow can HealthArc help you?
Interested in a demo or just general questions? Fill out the form below and a representative will respond shortly!
